Raboz 20 mg (Tablet (Enteric Coated))
Unit Price: ৳ 5.00 (50's pack: ৳ 250.00)
Medicine Details
Category | Details |
---|---|
Generic | Rabeprazole sodium |
Company | Leon pharmaceuticals ltd |
Indications
- Treatment of active duodenal ulcer
- Treatment of active benign gastric ulcer
- Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD)
- Long-term management of gastro-esophageal reflux disease (GERD Maintenance)
- Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD)
- Treatment of Zollinger-Ellison Syndrome
- Eradication of Helicobacter pylori in patients with peptic ulcer disease
Pharmacology
- Suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase
- Characterized as a gastric proton-pump inhibitor
Dosage
- Recommended oral dose for active duodenal ulcer and active benign gastric ulcer is 20 mg once daily
- Recommended oral dose for erosive or ulcerative gastro-esophageal reflux disease (GERD) is 20 mg once daily for four to eight weeks
- Maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending upon patient response for long-term management of GERD
Administration
- Rabeprazole tablets should be taken in the morning, before eating
- Tablets should not be chewed or crushed, but should be swallowed whole
Interaction
- Potential interaction with compounds whose absorption is pH dependent
- Co-administration with ketoconazole or itraconazole may result in a significant decrease in antifungal plasma levels
- No interaction with liquid antacids was observed
- Avoid co-administration with atazanavir
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- Contra-indicated in pregnancy and during breastfeeding
Side Effects
- Headache
- Diarrhoea
- Abdominal pain
- Vomiting
- Constipation
- Dry mouth
- Increased or decreased appetite
- Muscle pain
- Drowsiness
- Dizziness
Pregnancy & Lactation
- US FDA pregnancy category 'C'
- No adequate and well-controlled studies in pregnant women
- Likely to be excreted in human milk
Precautions & Warnings
- Symptomatic response to therapy does not preclude the presence of gastric or oesophageal malignancy
- Patients on long-term treatment should be kept under regular surveillance
- May increase the risk of hip, wrist, and spine fracture, predominantly in the elderly or in presence of other recognised risk factors
- Patients at risk of osteoporosis should have an adequate intake of vitamin D and calcium
- A risk of cross-hypersensitivity reactions with other proton pump inhibitor or substituted benzimidazoles cannot be excluded
- May increase the risk of gastrointestinal infections such as Salmonella, Campylobacter, and Clostridium difficile
Use in Special Populations
- No dosage adjustment is necessary for patients with renal or hepatic impairment
- Not recommended for use in children due to a lack of data on safety and efficacy
Overdose Effects
- Effects are generally minimal, representative of the known adverse event profile and reversible without further medical intervention
- No specific antidote is known
Therapeutic Class
- Proton Pump Inhibitor
Storage Conditions
- Keep below 30°C temperature, away from light & moisture
Chemical Structure
- Molecular Formula: C18H21N3O3S
Common Questions about Raboz 20 mg Tablet
- Proton pump inhibitor (PPI) that suppresses gastric acid secretion
- Used to treat duodenal ulcer, gastric ulcer, GERD, Zollinger-Ellison Syndrome, Helicobacter pylori eradication
- Common side effects include diarrhea, constipation, nausea, and vomiting
- Should be taken with food and not more than the prescribed dose
- Not recommended for use during pregnancy or breastfeeding
- Can cause dry mouth and constipation
- Long-term use can cause thinning of bones (osteoporosis)